AU2022275263A1 - Pharmaceutical composition for use in treating cerebral infarction - Google Patents

Pharmaceutical composition for use in treating cerebral infarction Download PDF

Info

Publication number
AU2022275263A1
AU2022275263A1 AU2022275263A AU2022275263A AU2022275263A1 AU 2022275263 A1 AU2022275263 A1 AU 2022275263A1 AU 2022275263 A AU2022275263 A AU 2022275263A AU 2022275263 A AU2022275263 A AU 2022275263A AU 2022275263 A1 AU2022275263 A1 AU 2022275263A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
cerebral infarction
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022275263A
Other languages
English (en)
Inventor
Keiji Hasumi
Kazuo Honda
Naoko Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Corxel Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corxel Pharmaceuticals Hong Kong Ltd filed Critical Corxel Pharmaceuticals Hong Kong Ltd
Publication of AU2022275263A1 publication Critical patent/AU2022275263A1/en
Assigned to JI XING PHARMACEUTICALS HONG KONG LIMITED reassignment JI XING PHARMACEUTICALS HONG KONG LIMITED Request for Assignment Assignors: BIOGEN MA INC.
Assigned to CORXEL PHARMACEUTICALS HONG KONG LIMITED reassignment CORXEL PHARMACEUTICALS HONG KONG LIMITED Amend patent request/document other than specification (104) Assignors: JI XING PHARMACEUTICALS HONG KONG LIMITED
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2022275263A 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction Pending AU2022275263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079820 2021-05-10
JP2021-079820 2021-05-10
PCT/US2022/028488 WO2022240810A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Publications (1)

Publication Number Publication Date
AU2022275263A1 true AU2022275263A1 (en) 2023-11-09

Family

ID=82214306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275263A Pending AU2022275263A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Country Status (9)

Country Link
US (1) US20240238248A1 (enExample)
EP (1) EP4337193A1 (enExample)
JP (1) JP2024525998A (enExample)
KR (1) KR20240005749A (enExample)
CN (1) CN117295497A (enExample)
AU (1) AU2022275263A1 (enExample)
BR (1) BR112023023534A2 (enExample)
CA (1) CA3216137A1 (enExample)
WO (1) WO2022240810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Ｓｍｔｐ一群又はｓｍｔｐ－７の製造中間体及びその化学的製造方法
CN121064221A (zh) * 2021-02-10 2025-12-05 福建盛迪医药有限公司 一种smtp-7衍生物及其用途
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Also Published As

Publication number Publication date
EP4337193A1 (en) 2024-03-20
BR112023023534A2 (pt) 2024-01-30
JP2024525998A (ja) 2024-07-16
US20240238248A1 (en) 2024-07-18
KR20240005749A (ko) 2024-01-12
CN117295497A (zh) 2023-12-26
CA3216137A1 (en) 2022-11-17
WO2022240810A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
US20090076105A1 (en) Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke
US20210236488A1 (en) Imatinib for use in the treatment of stroke
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
Hacke et al. General principles in the treatment of acute ischemic stroke
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
US20050255096A1 (en) Combination treatment for acute myocardial infarction
KR20230116002A (ko) 항혈전제로서 시클로스포린 유사체의 용도
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
KR20120038982A (ko) 노령 및 신장 손상 ｓｔ 비상승 심근 경색 환자의 치료를 위한 오타믹사반
Seestedt Jr et al. Intracerebral hemorrhage
JP4966019B2 (ja) 慢性移植片対宿主症におけるドライアイの予防および治療剤
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
CN111050768A (zh) 包含fgfr选择性酪氨酸激酶抑制剂的药物组合物
US20130253027A1 (en) Dosages of arylsulfonamide derivatives
US7252835B2 (en) Agent for preventing and/or treating sinusitis
JP4925406B2 (ja) 糖尿病性腎症の予防及び／又は治療剤
US20240316019A1 (en) Methods of preventing symptomatic ischemic stroke
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
US10517850B2 (en) Combination of TAFIa inhibitor with plasminogen activator
WO2007013842A1 (en) Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
Watson Principles of General Management and Treatment
Aronson Domenic A. Sica
HK1128620A (en) Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion injury in stroke

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JI XING PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER APPLICANT(S): BIOGEN MA INC.

HB Alteration of name in register

Owner name: CORXEL PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER NAME(S): JI XING PHARMACEUTICALS HONG KONG LIMITED